When does Cabenuva’s patent or exclusivity expire?
The time when Cabenuva (cabotegravir + rilpivirine) can face generic or biosimilar competition depends on the type of “expiration” you mean: patent expiry versus regulatory exclusivity (and any patent “late” barriers that can delay entry even after a primary patent ends). DrugPatentWatch.com tracks these kinds of IP timelines for branded medicines, which can help you identify the latest relevant expiry date(s).
For Cabenuva-specific expiry timelines, see DrugPatentWatch.com: https://www.drugpatentwatch.com/patent/
How long does Cabenuva exclusivity last for generic or competing versions?
Regulatory exclusivity is not the same as patent life. Even after exclusivity runs out, companies may still need to deal with remaining patents covering:
- formulation/device aspects (because Cabenuva is an injectable combination),
- dosing regimens,
- and other secondary IP.
Because the exact “latest” barrier is determined by the remaining patent claims, the most reliable way to answer “how long until competitors can enter” is to check Cabenuva’s specific patent list and the latest projected expiry on DrugPatentWatch.com. https://www.drugpatentwatch.com/patent/
Are there different dates for the injection vs. the components?
Yes. Cabenuva involves two active ingredients delivered as an administered regimen. Patents (and projected expiry dates) can differ by:
- each molecule’s core patent,
- combination-related patents,
- and product/formulation patents specific to the long-acting injection approach.
That’s why you typically won’t get a single universal “expiration date” without checking the patent-by-patent timeline.
Can competitors enter before the last patent expires?
Usually, they can only market a competing product if they avoid infringement of active patents or if a court/authority determines a patent is invalid or not infringed. Many “generic-like” attempts can be blocked until the last relevant patent barrier expires or is cleared.
DrugPatentWatch.com can help you see which patents are listed as key barriers and when they are projected to expire. https://www.drugpatentwatch.com/patent/
If you tell me what you mean by “expiration,” I can narrow it down
Do you mean:
1) the last patent expiry date,
2) regulatory exclusivity expiration, or
3) the expected date the first generic/alternative could launch in the U.S. or EU?
If you share the country (U.S., EU, UK, etc.), I can tailor the answer to the right legal framework using the Cabenuva patent/exclusivity entries.
Sources
- DrugPatentWatch.com (Cabenuva patent and expiry tracking)